Scarica l'app Stockscreener
1.985
2.32%
0.045
Fractyl Health Inc Borsa (GUTS) Ultime notizie
Fractyl, Bariendo developing off-ramp for post-GLP-1 maintenance - BioWorld MedTech
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide - marketscreener.com
Fractyl Health and Bariendo Sign Letter of Intent to - GlobeNewswire
Northern Trust Corp Sells 9,467 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Fractyl Health, Inc. (NASDAQ:GUTS) Shares Sold by Citadel Advisors LLC - Defense World
Transcript : Fractyl Health, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 05 - marketscreener.com
Fractyl Health submits first module of its CTA in Europe for RJVA-001 - TipRanks
Fractyl Health advances gene therapy for diabetes treatment By Investing.com - Investing.com South Africa
Fractyl Health advances gene therapy for diabetes treatment - Investing.com Australia
Fractyl Health Submits Clinical Trial Application in Europe - TipRanks
Fractyl Health Submits First Module of EU Trial Application for Gene Therapy RJVA-001 - marketscreener.com
Fractyl Health Unveils Promising Gene Therapy Data - TipRanks
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial ... - Eagle-Tribune
Fractyl Health Advances Rejuva® Gene Therapy Platform with - GlobeNewswire
Breakthrough One-Time Gene Therapy Could Replace Daily Diabetes Drugs, Heads to European Trials - Stock Titan
China On the March as U.S. Investors Plough Back in After Tariff Tension - The Globe and Mail
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 - The Manila Times
Fractyl Health Announces Promising Preclinical Data for RJVA-001, a Novel Gene Therapy for Type 2 Diabetes at ASGCT 2025 - Nasdaq
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data ... - Eagle-Tribune
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic - GlobeNewswire
Revolutionary One-Time GLP-1 Gene Therapy Achieves Powerful Diabetes Control with 5X Lower Side Effect Risk - Stock Titan
Prediction: Taiwan Semiconductor Stock Could Surge by 129% in the Next 5 Years - The Globe and Mail
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise - The Globe and Mail
Analysts and Institutions Continue to Bet Big on Alphabet - The Globe and Mail
16,400 Shares in Fractyl Health, Inc. (NASDAQ:GUTS) Bought by Raymond James Financial Inc. - Defense World
Fractyl signals accelerated enrollment for REMAIN-1 study while advancing Rejuva clinical milestones - MSN
Forge Biologics Inks AAV Development and cGMP Manufacturing Deal with Fractyl Health - Genetic Engineering and Biotechnology News
Fractyl Health Partners with Forge for Rejuva Gene Therapy Development - Contract Pharma
Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases - Business Wire
1 Super Stock Down 76% You'll Regret Not Buying on the Dip in 2025 - The Globe and Mail
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Fractyl Health Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Fractyl Health’s Q1 2025 shows rising R&D costs - Investing.com Nigeria
FRACTYL HEALTH, INC. SEC 10-Q Report - TradingView
Should You Buy Roku Stock Now With $500 and Hold for 10 Years? - The Globe and Mail
These High-Growth Stocks Were Down Over 50% This Year. Is It Time to Buy Them? - The Globe and Mail
Fractyl Health (GUTS) Expected to Announce Earnings on Tuesday - Defense World
Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference - The Manila Times
Fractyl Health to Report First Quarter 2025 Financial - GlobeNewswire
Fractyl Health Sets Date for Q1 Earnings, Showcases Diabetes Therapeutics at Major Healthcare Conference - Stock Titan
Geode Capital Management LLC Purchases 11,603 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Fractyl Health, Inc. to Present Preclinical Data on Rejuva Gene Therapy Platform at ASGCT 2025 Annual Meeting - Nasdaq
Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting - The Manila Times
Fractyl Health to Present Compelling Preclinical Data from - GlobeNewswire
Discover Fractyl Health And 2 More Promising Penny Stocks - Yahoo Finance
Fractyl Health (NASDAQ:GUTS) Earns Buy Rating from Analysts at Canaccord Genuity Group - Defense World
These Were the 2 Worst-Performing Stocks in the S&P 500 in March 2025 - The Globe and Mail
Fractyl Health initiated with a Buy at Canaccord - TipRanks
Meta Stock Holds Its Head Up High amid Full-Blown Legal Migraine - The Globe and Mail
Raymond James Financial Inc. Makes New Investment in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Sei Investments Co. Acquires Shares of 27,778 Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Norges Bank Makes New Investment in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Critical Analysis: Glaukos (NYSE:GKOS) & Fractyl Health (NASDAQ:GUTS) - Defense World
1.30%
3.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):